Tom Anderton is an attorney at TechLaw LLP, a patent attorney registered with the U.S. Patent and Trademark Office and admitted to practice law in California. He specializes in legal matters related to startups and has specific expertise in negotiation of all transactional documents and obtaining patent protection for chemical, pharmaceutical, biotech, and medical device inventions. He has been invited to lecture at UCSF, UCB and Stanford Law School.
Tom's Professional Profile
Prior to joining TechLaw, he was the Vice President, Intellectual Property & Legal Affairs at Presido Pharmaceuticals where he was responsible for developing and overseeing the IP portfolio and legal function at Presidio. Before Presidio, he was the Associate General Counsel and Chief Patent Counsel at Monogram Biosciences, Inc., where he built Monogram’s IP portfolio, which then was consistently recognized as one of the best IP portfolios in the US. Before going to Monogram, Tom was the Lead Attorney, Oncology at Genencor, Inc. where he developed and implemented Genencor’s oncology IP portfolio and led the due diligence team in their in-licensing of BL22, a lymphoma compound developed in Ira Pastan’s lab at the NCI. Prior to that, Tom was responsible for envisioning, creating, developing and implementing the patent strategy and portfolio related to the ‘virtual’ kinase, phosphatase and protease genes that SUGEN cloned from J. Craig Ventner’s early human genome sequencing efforts. He was also involved in developing the portfolio that relates to the current Pfizer compound SU11248 (SUTENT).
Tom drafted and prosecuted some of the early VEGF-related patents, such as those from Kari Alitalo’s group at the Ludwig Institute for Cancer Research. Before working in the biotech arena, Tom was focused on appellate, constitutional and First Amendment law and was responsible for co-writing trial briefs in the ISKCON v. City of Los Angeles (Hare Krishna/LAX) First Amendment case(s). Tom earned a J.D. from the Vermont Law School, a B.S. in molecular biology from UCSD and an M.S. in Cancer Biology from Stanford University. He has been consistently recognized by his peers as one of the most influential IP practitioners in the United States.